Le Lézard
Classified in: Health, Science and technology
Subjects: CALENDAR OF EVENTS, ANNUAL MEETINGS

Resverlogix Announces Annual and Special Meeting of Shareholders


CALGARY, Alberta, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that its Annual and Special Meeting of Shareholders (the "Meeting") is to be held Thursday, October 31, 2019 at Mount Royal University, Roderick Mah Centre for Continuous Learning ? Ross Glen Hall (Room EC1040), 4825 Mount Royal Gate SW, Calgary, Alberta, commencing at approximately 1:00 pm (MT).

A Notice of Meeting and Management Information Circular, containing the matters to be considered at the Meeting, will be delivered to shareholders and filed on SEDAR at www.sedar.com on or about Monday, September 30, 2019.

Following the formal business of the Meeting, Donald McCaffrey, President and Chief Executive Officer, will provide a corporate update presentation.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on:

For further information please contact:

Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the potential role of apabetalone in the treatment of high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


These press releases may also interest you

at 15:00
Local, regional and national leaders of the United Church of Christ announced Oct. 20 that church donations have wiped out $5.3 million in medical debt for 5,888 South Side Chicago families. Families in three ZIP codes are now receiving letters...

at 13:00
LiveWell TMS, a new depression treatment facility, announced today it will host a grand opening event on Thursday, October 24, in celebration of its new location and in honor of National Depression Awareness Month. Co-founded by doctors Nina and Eric...

at 12:00
JBRF is excited to announce the appointment of Elizabeth Errico as the organization's executive director. Ms. Errico moves into the role from her former position as a board member and the director of education. Ms. Errico joins the staff of JBRF as...

at 11:00
On the eve of the 43rd federal election, the Canadian Medical Association (CMA) is reminding Canadians to exercise their democratic right and vote. Throughout the campaign, it has become clear that health and health care are among Canadians' top...

at 04:00
VFS TasHeel, an authorised visa service provider for the Ministry of Foreign Affairs, the Kingdom of Saudi Arabia, announced that it has launched tourist visa services at its centres across 30 countries worldwide. Applicants will also be able to...

at 03:00
NY Laser Outlet - a one-stop-shop for the aesthetic Laser Industry that provides services Including buying, selling, renting, repairing laser devices and parts, as well as financing and clinical education ? has just announced the launch of their new...



News published on 22 august 2019 at 17:25 and distributed by: